Short-term outcomes of faricimab and aflibercept 8 mg in diabetic macular edema

Short-term outcomes of faricimab and aflibercept 8 mg in diabetic macular edema

Objective: To evaluate and compare the effectiveness and treatment burden of faricimab and aflibercept 8 mg in treatment-naive patients with diabetic macular edema (DME) using a pro re nata (PRN) protocol. Design: Retrospective, observational cohort study. Subjects: A total of 28 eyes from 18 treatm...

Full description

Saved in:

Bibliographic Details
Main Authors:	Carlo Maccauro, Yanny Jimenez Perez, Piergiorgio Neri, Ibraheem El Ghrably, Haytham I Salti, Francesco Pichi
Format:	Article
Language:	English
Published:	Elsevier 2025-07-01
Series:	AJO International
Subjects:	Diabetic macular edema Faricimab Aflibercept 8 mg Anti-VEGF therapy Comparative analysis Pro re nata protocol
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950253525000358
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials
by: Usha Chakravarthy, FRCOphth, PhD, et al.
Published: (2025-09-01)

Efficacy of Faricimab in the Treatment of Diabetic Macular Edema and Faricimab-Related Changes in OCT and OCT Angiography
by: Dorota Śpiewak, et al.
Published: (2025-06-01)

Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration
by: I. E. Ioshin, et al.
Published: (2019-08-01)

Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study
by: Chakraborty D, et al.
Published: (2024-11-01)

Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases
by: Kashiwagi I, et al.
Published: (2025-04-01)

Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration
by: Masaaki Saito, et al.
Published: (2025-08-01)

Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion
by: Toshiaki Hirakata, et al.
Published: (2025-07-01)

Effectiveness of aflibercept in treating bevacizumab resistant macular edema
by: Hussain Khudair Yassin
Published: (2024-12-01)

Corrigendum: Efficacy and safety of intravitreal injection of aflibercept biosimilar for treating diabetic macular edema
by: Gaixia Zhai, et al.
Published: (2025-05-01)

Real-World Data on Morphological and Functional Responses After Switching to Faricimab in Recalcitrant, Chronic Diabetic Macular Edema
by: Viktoria Deiters, et al.
Published: (2025-05-01)

Faricimab in the Treatment of Exudative Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Italy: The FARIT Real World Study
by: Marco Lupidi, et al.
Published: (2025-07-01)

Functional and Anatomical Outcomes of Faricimab in Previously Treated Wet Age-Related Macular Degeneration: Systematic Review and Pooled Analysis
by: Ali Khodor, et al.
Published: (2025-07-01)

Long-term results of anti-VEGF therapy in macular edema caused by central retinal vein occlusion
by: A. B. Galimova, et al.
Published: (2023-12-01)

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
by: Aljuhani HS, et al.
Published: (2025-06-01)

Efficacy of aflibercept in patients with neovascular age-related macular degeneration when combined with cataract surgery
by: A. A. Kuznetsov, et al.
Published: (2018-10-01)

Comparative efficacy of photodynamic therapy (PDT), ranibizumab, aflibercept monotherapy, and combination therapies for polypoidal choroidal vasculopathy: a network meta-analysis of randomized controlled trials
by: Miguel A. Quiroz-Reyes, et al.
Published: (2025-07-01)

New Drugs for the Treatment of DME and the Role of Biomarkers in Predicting Their Effectiveness
by: M. V. Budzinskaya, et al.
Published: (2023-01-01)

Changes of retinal ganglion cell–inner plexiform layer thickness and visual acuity in patients with diabetic macular edema treated with Aflibercept
by: Mouna M. Alsaad, et al.
Published: (2025-01-01)

Early Anatomical and Functional Outcomes of Faricimab in Recalcitrant Neovascular Age-Related Macular Degeneration: A Retrospective Real-World Study in an East-Asian Population
by: Yen-An Lai, et al.
Published: (2025-06-01)

Aflibercept for the therapy of retinal diseases. A review of clinical studies
by: T. D. Okhotsimskaya, et al.
Published: (2018-10-01)

Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom
by: Muiz Musadiq, et al.
Published: (2025-06-01)

Real-world outcomes of a loading phase with intravitreal faricimab in refractory Neovascular Age-Related Macular Degeneration (nAMD) patients
by: Xu Yufeng, et al.
Published: (2025-07-01)

Tomographic Parameters of Recurrent Macular Edema Due to Retinal Vein Occlusion during Antiangiogenic Therapy
by: D. Yu. Khokhlova, et al.
Published: (2021-10-01)

THE FIRST EXPERIENCE OF USING ANTI-VEGF THERAPY PRIOR TO CATARACT SURGERY IN PATIENTS WITH DIABETIC MACULAR EDEMA
by: N. A. Malysheva
Published: (2018-10-01)

Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration
by: Bhagya Weerasinghe, et al.
Published: (2021-01-01)

Metabolomics analysis uncovers metabolic changes and remodeling of anti-VEGF therapy on macular edema
by: Congcong Yan, et al.
Published: (2025-07-01)

Сlinical, functional and morphological results of diabetic macular edema antiangiogenic treatment in patients with diabetes mellitus type two
by: L. K. Moshetova, et al.
Published: (2014-07-01)

Unraveling the effects of serial intravitreal Aflibercept injections on the ocular surface of patients with glaucoma and retinal comorbidity
by: Luca Agnifili, et al.
Published: (2025-04-01)

Switching to Faricimab for Polypoidal Choroidal Vasculopathy with Real-World Outcomes in Refractory Cases &ndash; The FAR-PEARL Study Report 1
by: Fong KC, et al.
Published: (2025-07-01)

Safety Evaluation of Bilateral Same-Day Intravitreal Injection of Faricimab
by: Michael D. Karampelas, et al.
Published: (2025-06-01)

A machine learning model for predicting anatomical response to Anti-VEGF therapy in diabetic macular edema
by: Wenrui Lu, et al.
Published: (2025-05-01)

Full-Thickness Macular Hole Formation After Intravitreal Faricimab Injection for Polypoidal Choroidal Vasculopathy
by: Tavonvunchai F, et al.
Published: (2025-06-01)

Evaluation of Flowmetry Indicators in Patients with a Wet AMD Form during Antiangiogenic Therapy
by: N. Yu. Yousef, et al.
Published: (2019-12-01)

Ensemble machine learning algorithm for anti-VEGF treatment efficacy prediction in diabetic macular edema
by: Yu Fang, et al.
Published: (2025-07-01)

Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration
by: S. V. Nedogoda, et al.
Published: (2020-03-01)

Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy
by: Wael Ahmed Ewais, et al.
Published: (2025-06-01)

A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents
by: Kiran Turaka
Published: (2014-04-01)

Postoperative, or pseudophakic, macular edema
by: I. E. Ioshin
Published: (2020-12-01)

Effects of switching from intravitreal injection of aflibercept to faricimab on ocular blood flow in patients with diabetic macular edema
by: Yoshinari Saima, et al.
Published: (2024-06-01)

Uso de regorafenibe em pacientes com câncer colorretal metastático previamente tratados com bevacizumabe ou aflibercepte: experiência clínica uni-institucional
by: Rodrigo Nogueira Fogace, et al.
Published: (2017-10-01)